Literature DB >> 19001560

Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.

Adrian Covic1, Prajesh Kothawala, Myriam Bernal, Sean Robbins, Arpi Chalian, David Goldsmith.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a powerful risk factor for all-cause mortality and its most common aetiology, cardiovascular (CV) mortality. Mineral metabolism disturbances occur very early during the course of CKD but their control has been poor. A number of studies have assessed the relationship between all-cause mortality, CV mortality and events with mineral disturbances in CKD patients, but with considerable discrepancy and heterogeneity in results. Thus, a systematic review was conducted to assess methodological and clinical heterogeneity by comparing designs, analytical approaches and results of studies.
METHODS: Medline, EMBASE and Cochrane databases were systematically searched for articles published between January 1980 and December 2007.
RESULTS: Thirty-five studies were included in the review. All-cause mortality was the most commonly assessed outcome (n = 29). Data on CV mortality risk (n = 11) and CV events (congestive heart failure, stroke, myocardial infarction) (n = 4) are limited. The studies varied in populations scrutinized, exposure assessments, covariates adjusted and reference mineral levels used in risk estimation. A significant risk of mortality (all-cause, CV) and of CV events was observed with mineral disturbances. The data supported a greater mortality risk with phosphorus, followed by calcium and parathyroid hormone (PTH). The threshold associated with a significant all-cause mortality risk varied from 3.5-3.9 mg/dL (reference: 2.5-2.9) to 6.6-7.8 mg/dL (reference: 4.4-5.5) for high phosphorus, <3 mg/dL (reference: 5-7) to <5 mg/dL (reference: 5-6) for low phosphorus, 9.7-10.2 mg/dL (reference: < or =8.7) to >10.5 mg/dL (reference: 9-9.5) for high calcium, < or =8.8 mg/dL (reference: >8.8) to <9 mg/dL (reference: 9-9.5) for low calcium and >300 pg/mL (reference: 200-300) to >480 pg/mL (reference: < or =37) for PTH. Thresholds at which the CV mortality risk significantly increased were >5.5 (reference: 3.5-5.5) and >6.5 mg/dL (reference: <6.5) for phosphorus and >476.1 pg/mL (reference: <476.1) for PTH.
CONCLUSIONS: Serious limitations were observed in the quality and methodology across studies. In spite of enormous heterogeneity across studies, a significant mortality risk was observed with mineral disturbances in dialysis patients. Data on risk in pre-dialysis patients were less conclusive due to even more limited (numerically) evidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001560     DOI: 10.1093/ndt/gfn613

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  75 in total

1.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  The protective effect of ENA Actimineral resource A on CCl4-induced liver injury in rats.

Authors:  Il-Hwa Hong; Hoon Ji; Sung-Yong Hwa; Won-Il Jeong; Da-Hee Jeong; Sun-Hee Do; Ji-Min Kim; Mi-Ran Ki; Jin-Kyu Park; Moon-Jung Goo; Ok-Kyung Hwang; Kyung-Sook Hong; Jung-Youn Han; Hae-Young Chung; Kyu-Shik Jeong
Journal:  Mar Biotechnol (NY)       Date:  2010-10-05       Impact factor: 3.619

Review 3.  Atherosclerosis in CKD: differences from the general population.

Authors:  Tilman B Drüeke; Ziad A Massy
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

Review 4.  Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Authors:  David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith
Journal:  Am J Kidney Dis       Date:  2015-02-26       Impact factor: 8.860

5.  Chronic kidney disease: epic battles in the phosphate-binder wars-the last episode?

Authors:  Adrian Covic; Luminita Voroneanu
Journal:  Nat Rev Nephrol       Date:  2013-07-30       Impact factor: 28.314

6.  Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients.

Authors:  Hee Jung Jeon; Yong Chul Kim; Seokwoo Park; Clara Tammy Kim; Jongwon Ha; Duck Jong Han; Jieun Oh; Chun Soo Lim; In Mok Jung; Curie Ahn; Yon Su Kim; Jung Pyo Lee; Young Hoon Kim
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

Review 7.  Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers.

Authors:  David J A Goldsmith; John Cunningham
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 8.  Phosphate binders in patients with chronic kidney disease.

Authors:  Samuel Chan; Kenneth Au; Ross S Francis; David W Mudge; David W Johnson; Peter I Pillans
Journal:  Aust Prescr       Date:  2017-02-01

9.  Dietary phosphorus intake and distribution in Chinese peritoneal dialysis patients with and without hyperphosphatemia.

Authors:  Na Jiang; Wei Fang; Xiaoxiao Yang; Lin Zhang; Jiangzi Yuan; Aiwu Lin; Zhaohui Ni; Jiaqi Qian
Journal:  Clin Exp Nephrol       Date:  2014-09-05       Impact factor: 2.801

10.  Cinacalcet may improve oxidative DNA damage in maintenance hemodialysis patients: an observational study.

Authors:  Elif Ari; Yuksel Kaya; Halit Demir; Ebru Asicioglu; Zehra Eren; Eray Celik; Hakki Arikan
Journal:  Int Urol Nephrol       Date:  2014-05-09       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.